Selected Publications
Cannas S, Till JE, Kim K, LaRiviere MJ, Vollmer CM, Eads JR, Karasic TB, O'Dwyer PJ, Schneider CJ, Teitelbaum UR, Reiss Binder KA, O'Hara MH, Ross DT, McGregor K, Bornemann-Kolatszki K, Schutz E, Beck J, Carpenter EL: Liquid biopsy signature combining copy number instability and mutant KRAS
detection is associated with survival for patients with metastatic pancreatic cancer AACR Annual meeting, Orlando, FL : 2023.
Wiess S, Speicher LA, Brozena LJ, Xu J, Luke RA, Rivera JI, Aprelev P, Nunez-Cruz S, Milone MC, Sterman DH, O'Hara MH, Haas AR, Tanyi JL, Johnson LA: A Phase 1 KIR-CAR Clinical Trial for Patients with Cholangiocarcinoma,
Mesothelioma, or Ovarian Cancers Cholangiocarcinoma Foundation Annual Meeting, Salt lake City, Utah : 2023.
Lyman JP, Cabanski CR, Maddock S, Wolff RA, Wainberg ZA, Ko AH, Rahma O, Fisher G, Gabriel PE, Doucette A, Zheng-Lin B, Maloy MA, Dugan U, Fairchild J, Spasic M, O'Donnell-Tormey J, Vonderheide RH, O'Hara MH, O'Reilly EM: Clinical Benefit of Granulocyte-Colony Stimulating Factor (GCSF) Use During Chemoimmunotherapy Treatment for Metastatic Pancreatic Adenocarcinoma (mPDAC) American Society of Clinical Oncology GI Symposium, San Francisco, CA : 2023.
Sanborn RE, Gabrail N, Carneiro B, O'Hara MH, Bordoni R, Gordon M, Khalil D, Hauke RJ, Taglienti C, Rogalski M, Styles. R, Alvarado D, Maurer D, Malenchek L, Murphy M, Vitale L, Hawthorne T, Morani P, Thomas L, Keler T, Yellin M: Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab Society for Immunotherapy for Cancer Annual Meeting, Boston, MA : 2022 .
Friedman CF, Carvajal RC, Davar D, Castanon E, Ascierto PA, Calvo E, O'Hara MH, Powell S, Shapira-Frommer R, Garralda E, Renouf DJ, Perets R, Yunan M, Ravindran P, Hammell A, O'Brien S, Xu, K, Wilson N, Jhatakia A, Mukhopadhyay A, Gutierrez M: Phase 1/2a study of the novel nonfucosylated anti-CTLA4 monoclonal antibody BMS-986218 +/- nivolumab in advanced solid tumors: Part 1 results Society for Immunotherapy of Cancer Annual Meeting, Boston, MA : 2022.
O'Hara MH, Bear A, Wattenberg M, Teitelbaum ur, Reiss KA, Karasic TB, Schneider C, O’Dwyer PJ, Ben-Josef E, Wojcieszynski AP, Maity A, Mick R, Vonderheide RH: Phase 1 study of hypofractionated radiation in combination with tremelimumab and durvalumab in refractory metastatic pancreatic adenocarcinoma American Association for Cancer Research Special Conference: Pancreatic Cancer, Boston, MA : 2022.
Karasic TB, Brown TJ, Schneider C, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O'Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O'Dwyer PJ: Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer Oncologist 27 (9): 716-e689,2022.
Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, Karasic T, Tondon R, Onyiah C, Gosselin MK, Donze A, Domchek SM, Vonderheide RH: Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial Lancet Oncology 23 (8): 1009-1020,2022.
Chapin WJ, Till JE, Hwang WT, Eads JR, Karasic TB, O'Dwyer PJ, Schneider CJ, Teitelbaum UR, Romeo J, Black TA, Christensen TE, Redlinger Tabery C, Anderson A, Slade M, LaRiviere M, Yee SS, Reiss KA, O'Hara MH, Carpenter EL: Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma JCO Precis Oncol
6 : e2200060,2022.
Padrón LJ*, Maurer DM*, O'Hara MH*, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine 28 (6): 1167-1177,2022.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-360-0735
Patient appointments: 800-789-7366